Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People With Down Syndrome

NCT07278492 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT07278492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07278492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People With Down Syndrome
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
May 31, 2028
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome (ds)